Elsevier Inc.

SHERPA: Unknown

People

  1. Riely
    Riely
  2. Kris
    Kris
  3. Drilon
    Drilon
  4. Ladanyi
    Ladanyi
  5. Offin
    Offin
  6. Schoenfeld
    Schoenfeld
  7. Yu
    Yu
  8. Rekhtman
    Rekhtman
  9. Rudin
    Rudin
  10. Arcila
    Arcila

Groups

  1. Department of Medicine (16)
  2. Sloan Kettering Institute Postdocs (16)
  3. Solid Tumor Oncology Division (16)
  4. Thoracic Oncology (16)
  5. GSK Faculty (15)
  6. Human Oncology and Pathogenesis Program (13)
  7. Tow Center for Developmental Oncology (TCDO) (11)
  8. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (10)
  9. Epidemiology and Biostatistics (7)
  10. Hematologic Malignancies, Division of (7)
Search Within
  1. "Gregory Riely"
  2. "Sloan Kettering Institute Postdocs"
Formats
  1. Meeting Abstract (10)
  2. Journal Article (6)
Groups
  1. Department of Medicine (16)
  2. Sloan Kettering Institute Postdocs (16)
  3. Solid Tumor Oncology Division (16)
  4. Thoracic Oncology (16)
  5. GSK Faculty (15)
  6. Human Oncology and Pathogenesis Program (13)

More Groups

People
  1. Gregory Riely (16)
  2. Marc Ladanyi (11)
  3. Mark Kris (10)
  4. Charles Rudin (9)
  5. Romel Somwar (8)
  6. Adam Schoenfeld (7)

More People

Years
  1. 2023 (4)
  2. 2020 (2)
  3. 2019 (5)
  4. 2018 (2)
  5. 2017 (2)
  6. 2015 (1)
Publications
  1. Journal of Thoracic Oncology (16)

Results (16)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Clinical characteristics and outcomes of patients with EGFR-mutant lung cancer with acquired BRAF alterations
    Meeting Abstract

    Sui, J.; Yang, S. R.; Bowman, A. S.; Vankayala, P.; Falcon, C.; Somwar, R.; Drilon, A. E.; Riely, G. J.; Kris, M. G.; Ladanyi, M.; more...
    Journal of Thoracic Oncology (2023)

    Fulltext@MSK | Save
  • Understanding genomic and social determinants of cancer immunotherapy outcome across ancestry
    Meeting Abstract

    Carrot-Zhang, J.; Fong, C.; Waters, M.; Pichotta, K.; Jee, J.; Jutagir, D.; Ma, D.; Perea-Chamblee, T.; Kim, S.; Arora, K.; more...
    Journal of Thoracic Oncology (2023)

    Fulltext@MSK | Save
  • Combination therapy with MDM2 and MEK inhibitors is effective in patient-derived models of lung adenocarcinoma with concurrent oncogenic drivers and MDM2 amplification
    Journal Article

    Elkrief, A.; Odintsov, I.; Markov, V.; Caeser, R.; Sobczuk, P.; Tischfield, S. E.; Bhanot, U.; Vanderbilt, C. M.; Cheng, E. H.; Drilon, A.; more...
    Journal of Thoracic Oncology (2023)

    Fulltext@MSK | Save
  • Molecular biomarkers of disease outcomes and mechanisms of acquired resistance to first-line osimertinib in advanced EGFR-mutant lung cancers
    Journal Article

    Choudhury, N. J.; Marra, A.; Sui, J. S. Y.; Flynn, J.; Yang, S. R.; Falcon, C. J.; Selenica, P.; Schoenfeld, A. J.; Rekhtman, N.; Gomez, D.; more...
    Journal of Thoracic Oncology (2023)

    Fulltext@MSK | Save
  • The genomic landscape of SMARCA4 alterations and association with patient outcomes in lung cancer
    Meeting Abstract

    Schoenfeld, A. J.; Montecalvo, J.; Namakydoust, A.; Lavery, J.; Bandlamudi, C.; Rizvi, H.; Paul, S.; Arcila, M.; Chang, J.; Sauter, J.; more...
    Journal of Thoracic Oncology (2020)

    Fulltext@MSK | Save
  • SMARCA4-deficient thoracic sarcomatoid tumors represent primarily smoking-related undifferentiated carcinomas rather than primary thoracic sarcomas
    Journal Article

    Rekhtman, N.; Montecalvo, J.; Chang, J. C.; Alex, D.; Ptashkin, R. N.; Ai, N.; Sauter, J. L.; Kezlarian, B.; Jungbluth, A.; Desmeules, P.; more...
    Journal of Thoracic Oncology (2020)

    Fulltext@MSK | Save
  • A novel activating MAP2K1 in-frame deletion mediates acquired resistance to ROS1 TKIs in a patient with ROS1 fusion-positive NSCLC
    Meeting Abstract

    Sato, H.; Schoenfeld, A.; Siau, E.; Suzawa, K.; Yue, C.; Offin, M.; Drilon, A.; Davare, M.; Riely, G.; Ladanyi, M.; more...
    Journal of Thoracic Oncology (2019)

    Fulltext@MSK | Save
  • Tissue-based molecular and histologic landscape of acquired resistance to osimertinib in patients with EGFR-mutant lung cancers
    Meeting Abstract

    Schoenfeld, A.; Chan, J.; Rizvi, H.; Somwar, R.; Kubota, D.; Daneshbod, Y.; Chang, J.; Offin, M.; Arcila, M.; Pe'Er, D.; more...
    Journal of Thoracic Oncology (2019)

    Fulltext@MSK | Save
  • Molecular characteristics, immunophenotype, and immune checkpoint inhibitor response in BRAF non-V600 mutant lung cancers
    Meeting Abstract

    Offin, M.; Pak, T.; Mondaca, S.; Montecalvo, J.; Rekhtman, N.; Halpenny, D.; Wu, S.; Kris, M.; Paik, P.; Riely, G.; more...
    Journal of Thoracic Oncology (2019)

    Fulltext@MSK | Save
  • Concurrent RB1 and TP53 alterations define a subset of EGFR-mutant lung cancers at risk for histologic transformation and inferior clinical outcomes
    Journal Article

    Offin, M.; Chan, J. M.; Tenet, M.; Rizvi, H. A.; Shen, R.; Riely, G. J.; Rekhtman, N.; Daneshbod, Y.; Quintanal-Villalonga, A.; Penson, A.; more...
    Journal of Thoracic Oncology (2019)

    Fulltext@MSK | Save